ghk-cu clinical trials side effects Effects: What Does the Research Say? Doctor Explains GHK-Cu Peptide Benefits and Side

The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough

Havent noticed any weight loss

doi: 10.1038/s41387-022-00181-8

Predictably, results showed that different doses of Dihexa-treated APP/PS1 mice increased the levels of AngIV

Watch out for these red flags to avoid low-quality peptides